Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches

Featuring an interview with Dr Sarah Sammons, including the following topics:

• Development of brain metastases in patients with HER2-positive and HER2-negative breast cancer (0:00)
• Local therapy approaches for the treatment of brain metastases (8:23)
• Treatment options for patients with HER2-positive breast cancer and CNS-only disease progression (16:36)
• Clinical presentation of leptomeningeal disease; management of functional sequelae associated with brain metastases (19:07)
• Investigational agents for the treatment of brain metastases in HER2-positive breast cancer (25:01)
• Case: A 65-year-old woman with ER-negative, HER2-positive metastatic breast cancer (mBC) develops a single 6-mm brain metastasis after 4 years of maintenance trastuzumab/pertuzumab (27:38)
• Screening for brain metastases; radiation necrosis as a side effect of radiation therapy (31:00)
• Case: A 39-year-old woman with ER-negative, HER2-positive mBC develops 7 new brain metastases 6 months into treatment with a taxane, trastuzumab and pertuzumab (34:30)

CME information and select publications